Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.59 |
| ▸ | TTPA | P49638 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672019 | 1.00 | NR1I2 (0.61) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL5672022 | 1.00 | NR1I2 (0.61) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL26427359 | 0.88 | NR1I2 (0.48) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL26427552 | 0.88 | NR1I2 (0.48) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL15150901 | 0.88 | NR1I2 (0.48) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL4271100 | 0.88 | NR1I2 (0.65) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL30859422 | 0.88 | NR1I2 (0.65) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL8935461 | 0.88 | NR1I2 (0.65) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL8935467 | 0.88 | NR1I2 (0.65) | NR1I2MAPTLMNAKMT2AUSP2 | |
| SCHEMBL23692465 | 0.87 | MAPT (0.59) | NR1I2MAPTLMNAKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| EP-0566718-A1 | STABILIZERS FOR PLASTIC MATERIALS | Ciba SC Holding AG (CH) | 1993-10-27 | — | — | EP | claimed |
| WO-1993010175-A1 | STABILIZERS FOR PLASTIC MATERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-27 | — | — | WO | claimed |
| EP-0445735-A1 | Melanogenesis-inhibiting endermic preparation | Sansho Seiyaku Co., Ltd. (JP) | 1991-09-11 | — | — | EP | claimed |
| JP-1068366-A | — | — | None | — | — | JP | disclosed |
| US-11717490-B2 | Therapeutic nanocarrier system and methods of use | UNIVERSITY OF CYPRUS (CY) | 2023-08-08 | — | — | US | disclosed |
| EP-4161492-A1 | THERAPEUTIC NANOCARRIER SYSTEM AND METHODS OF USE | University Of Cyprus (CY) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021069753-A1 | NEW PROCESS FOR THE MANUFACTURE OF FEED ADDITIVES OF CAROTENOIDS | DSM IP ASSETS B.V. (NL) | 2021-04-15 | — | — | WO | disclosed |
| EP-3377179-B1 | DEUTERATED EPI-743 | CONCERT PHARMACEUTICALS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3377179-B1 | DEUTERATED EPI-743 | CONCERT PHARMACEUTICALS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-4201879-A | Hydroquinones | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4189612-A | S-(+) 2,3,6-trimethyl-5-(2,2,4-trimethyl-1,3-dioxolane-4-ethyl)phenol | HOFFMANN-LA ROCHE INC. (US) | 1980-02-19 | — | — | US | disclosed |
| US-4182719-A | Synthesis of optically active vitamin E | HOFFMAN-LA ROCHE INC. (US) | 1980-01-08 | — | — | US | disclosed |
| US-4153614-A | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein | HOFFMANN-LA ROCHE INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4153614-A | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein | HOFFMANN-LA ROCHE INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4151177-A | Synthesis of optically active vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4113740-A | Synthesis of optically active vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | NR1I2 2593/4885MAPT 37/4885LMNA 260/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | NR1I2 2663/4885MAPT 159/4885LMNA 384/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | NR1I2 2663/4885MAPT 159/4885LMNA 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.